BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 19088695)

  • 21. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.
    Hadi M; Chen CC; Whatley M; Pacak K; Carrasquillo JA
    J Nucl Med; 2007 Jul; 48(7):1077-83. PubMed ID: 17574980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First Experience Using
    Kessler L; Schlitter AM; Krönke M; von Werder A; Tauber R; Maurer T; Robinson S; Orlandi C; Herz M; Yousefi BH; Nekolla SG; Schwaiger M; Eiber M; Rischpler C
    J Nucl Med; 2021 Apr; 62(4):479-485. PubMed ID: 32859709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
    Jungels C; Karfis I
    Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
    Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
    Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
    Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
    Rufini V; Treglia G; Perotti G; Giordano A
    Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison.
    Bomanji J; Levison DA; Flatman WD; Horne T; Bouloux PM; Ross G; Britton KE; Besser GM
    J Nucl Med; 1987 Jun; 28(6):973-8. PubMed ID: 3585505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of 123I-MIBG Scintigraphy in Paraganglioma.
    Milardovic R; Corssmit EP; Stokkel M
    Neuroendocrinology; 2010; 91(1):94-100. PubMed ID: 19786729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma.
    Sung C; Lee HS; Lee DY; Kim YI; Kim JE; Lee SJ; Oh SJ; Sung TY; Lee YM; Kim YH; Kim BJ; Koh JM; Lee SH; Ryu JS
    Clin Nucl Med; 2024 Jan; 49(1):27-36. PubMed ID: 38054497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
    Fukuoka M; Taki J; Mochizuki T; Kinuya S
    Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
    Lugat A; Drui D; Mirallié E; Kraeber-Bodéré F; Ansquer C
    Clin Nucl Med; 2019 Sep; 44(9):738-740. PubMed ID: 31306205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
    Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
    Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
    Shulkin BL; Thompson NW; Shapiro B; Francis IR; Sisson JC
    Radiology; 1999 Jul; 212(1):35-41. PubMed ID: 10405717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas.
    Jing H; Li F; Wang L; Wang Z; Li W; Huo L; Zhang J
    Clin Nucl Med; 2017 Jul; 42(7):525-529. PubMed ID: 28481789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
    Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.